Hinolon
Hinolon je familija sintetičkih antibiotika širokog spektra[1][2][3] Prva generacija hinolona je počela uvođenjem nalidiksinske kiselne tokom 1962 za lečenje infekcija urinarnog trakta kod ljudi.[4] Nalidiksinsku kiselinu je otkrio Džordž Lešer sa saradnicima tokom pokušaja sinteze hlorohina.[5]
Oni sprečavaju odvijanje i dupliranje bakterijske DNK.[6]
Hinoloni, u poređenju sa drugim klasama antibiotika, nose veći rizik od kolonizacije sa MRSA i Clostridium difficile.[7][8][9] Večina hinolona u kliničkoj upotrebi pripada grupi fluorohinolona, koji imaju atom fluora vezan za centralni prsten, tipično u poziciji 6, ili na C-7.
Reference
uredi- ↑ Andriole, VT The Quinolones. Academic Press, 1989.
- ↑ Andersson, MI, MacGowan, AP. Development of the quinolones. J. Antimicrob. Chemother. (2003) 51, Suppl. S1, 1–11 DOI: 10.1093/jac/dkg212.
- ↑ Ivanov DV, Budanov SV (2006). „[Ciprofloxacin and antibacterial therapy of respiratory tract infections]” (Russian). Antibiot. Khimioter. 51 (5): 29–37. PMID 17310788.
- ↑ sanofi-aventis U.S. LLC (September 2008). „NegGram Caplets (nalidixic acid, USP)” (PDF). USA: FDA.
- ↑ Wentland MP: In memoriam: George Y. Lesher, Ph.D., in Hooper DC, Wolfson JS (eds): Quinolone antimicrobial agents, ed 2., Washington DC, American Society for Microbiology : XIII - XIV, 1993.
- ↑ Hooper, DC. (March 2001). „Emerging mechanisms of fluoroquinolone resistance” (PDF). Emerg Infect Dis 7 (2): 337–41. DOI:10.3201/eid0702.010239. PMC 2631735. PMID 11294736.
- ↑ Muto, CA.; Jernigan, JA.; Ostrowsky, BE.; Richet, HM.; Jarvis, WR.; Boyce, JM.; Farr, BM. (May 2003). „SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus”. Infect Control Hosp Epidemiol 24 (5): 362–86. DOI:10.1086/502213. PMID 12785411.
- ↑ Dr Ralf-Peter Vonberg. „Clostridium difficile: a challenge for hospitals”. European Center for Disease Prevention and Control. Institute for Medical Microbiology and Hospital Epidemiology: IHE. Arhivirano iz originala na datum 2009-06-11. Pristupljeno 27. 7. 2009.
- ↑ Tacconelli, E.; De Angelis, G.; Cataldo, MA.; Pozzi, E.; Cauda, R. (January 2008). „Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis”. J Antimicrob Chemother 61 (1): 26–38. DOI:10.1093/jac/dkm416. PMID 17986491.